ArticleMikrochimica acta2026
Covalent organic polymer-based biosensor for autism spectrum disorder biomarker detection.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
A novel covalent organic polymer based on proflavine (COP-PF) is designed, synthetized and characterized to be used as a redox indicator in the biosensing field. COP-PF is introduced as an intrinsic redox indicator, ensuring reliable signal transduction without the need for external mediators. The platform was further reinforced with few-layer bismuthene, which is employed to structure gold screen-printed electrodes (AuSPE), improving electron transfer and DNA immobilization. Lastly, DNA nanoengineering is proposed in the shape of tetrahedral DNA nanostructures (TDNs) whose thiol-functionalized basal vertices enabled robust anchoring to FLB, while their apex carried a complementary probe to the analyte. The synergy of these materials yielded a highly robust biosensing system with exceptional sensitivity and selectivity. Biologically, the platform was applied to the detection of miRNA-27a, a clinically relevant biomarker of autism spectrum disorder (ASD), whose diagnosis has attracted the attention of the scientific community and society at large. The device achieved an ultralow detection limit of 10.3 aM, maintained high specificity in the presence of potential interferents, and demonstrated successful performance in spiked human serum samples. These results underscore the value of integrating emerging 2D nanomaterials, DNA nanotechnology, and functional organic polymers to advance medical diagnostics, offering a versatile route for nucleic acid biomarker detection in complex biological environments. Clinical trial number: not applicable.
Indexed as
Identifiers
41483201What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.